AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Phase II clinical trial data presented on topical alprostadil.

OBGYN & Reproduction Week

| November 22, 2004 | COPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2004 NOV 22 - (NewsRx.com & NewsRx.net) -- Vivus Inc. (Nasdaq:VVUS) investigators presented positive results of a Phase II clinical study evaluating the safety and efficacy of the company's product Alista (topical alprostadil) for the treatment of female sexual arousal disorder (FSAD) in premenopausal women.

The data were reported at the Annual Meeting of the International Society for the Study of Women's Sexual Health (ISSWSH). Stephanie Kuffel, PhD, acting instructor, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, presented the findings on October 30, 2004.

Kuffel provided a detailed analysis of previously announced results of a double-blind, placebo-controlled, crossover-design study that evaluated the response to Alista administered at home by 51 premenopausal women diagnosed with FSAD.

The study demonstrated that treatment with Alista significantly increased the number of successful and satisfactory sexual events by 48% over placebo (p

Additionally, and as reported earlier, the study showed that 64% of Alista doses resulted in satisfactory sexual events (p

"Female sexual arousal disorder is a common yet largely under treated condition," said Kuffel. "These results with Alista appear encouraging for the treatment of premenopausal women with FSAD. We are hopeful that this work, coupled with additional clinical studies, will lead to a greater understanding of FSAD and the availability of effective treatments for women who are impacted by this condition."

In ...

Related articles from newspapers, magazines, journals, and more
Harvard Scientific Completes Animal Toxicity Studies For FSAD -- "Female Sexual...
Press release article from: Business Wire September 23, 1998 700+ words
...treatment product for female sexual arousal disorder ("FSAD"). In the studies...the Management of Female Sexual Dysfunction" conference...23-25, at the FSAD conference. The...vaginal dryness, female sexual disorder and female...
Neutron Signs Letter of Intent to Acquire up to 67% Interest in Development...
Press release article from: PR Newswire March 10, 2004 700+ words
...the treatment of Female Sexual Arousal Disorder (FSAD). - Endeavors...the treatment of Female Sexual Arousal Disorder (FSAD). The Company...pharmaceutical treatment for Female Sexual Arousal Disorder...from some form of FSAD. The Company to...
NexMed to Initiate 400 Femprox(R) Clinical Study in China For Female Sexual...
Press release article from: PR Newswire March 2, 2004 700+ words
...cream in patients diagnosed with female sexual arousal disorder (FSAD). Femprox(R), recently...menopausal women diagnosed with FSAD completed the four-week clinical...in patients aged 21-45 with FSAD. The clinical efficacy reported...
Zestra for Women(TM) Increases Sexual Pleasure in Women With FSAD (Female...
Press release article from: PR Newswire November 20, 2001 700+ words
...oil formulated to enhance female sexual pleasure, increase warmth...WOMEN(TM) IN WOMEN WITH FEMALE SEXUAL AROUSAL DISORDER. Zestra...was studied in 10 women with Female Sexual Arousal Disorder (FSAD), in at-home use. Zestra...
NexMed to initiate 400 Femprox clinical study in China for female sexual...
News wire article from: Asia Africa Intelligence Wire March 2, 2004 700+ words
...safety of Femprox cream in patients diagnosed with female sexual arousal disorder (FSAD). Femprox, recently profiled on CBS 20/20...ninety-eight pre-menopausal women diagnosed with FSAD completed the four-week clinical study in an...
PRESS RELEASE: Zestra for Women increases sexual pleasure in women with FSAD...
News wire article from: Chemical Business Newsbase November 26, 2001 700+ words
...Zestra for Women presented at the "Female Sexual Function Forum" (FSFF) in Boston...feminine massage oil formulated to enhance female sexual pleasure, increase warmth, sensitivity...Women was studied in 10 women with Female Sexual Arousal Disorder, in at-home use...
Study confirms at least two subtypes of FSAD.(Gynecology)
Magazine article from: OB GYN News Finn, Robert March 1, 2005 700+ words
...Disorders defines only one type of female sexual arousal disorder, there is...Research. For a diagnosis of female sexual arousal disorder (FSAD), DSM-IV-TR requires...reporting the genital subtype of FSAD, 26 reporting the subjective...
Vivus Phase III with Alprostadil aiming at 'Huge' FSAD market.
Newspaper article from: Bioworld Financial Watch Osborne, Randall September 13, 2004 700+ words
...socio-economic as medical, female sexual arousal disorder (FSAD) has been overlooked in favor...Viagra from Pfizer Inc. But FSAD is real. It's believed to...trial with its drug Alista for FSAD. Alista, to be tested at 40...
Study supports subtypes of female sexual arousal disorder.(Women's Health)
Magazine article from: Family Practice News Finn, Robert April 1, 2005 700+ words
...Disorders defines only one type of female sexual arousal disorder, there is...Research. For a diagnosis of female sexual arousal disorder (FSAD), DSM-IV-TR requires...Although some women with FSAD do complain chiefly of genital...
Positive Clinical Data in Treating Female Sexual Arousal Disorder From VIVUS To...
Press release article from: PR Newswire October 28, 2004 700+ words
...the treatment of Female Sexual Arousal Disorder (FSAD) in premenopausal...active drug. "Female sexual arousal disorder...premenopausal women with FSAD. We are hopeful...treatment of women with Female Sexual Arousal Disorder (FSAD). FSAD is one...
For more facts and information, see all results

Source: HighBeam Research, Phase II clinical trial data presented on topical alprostadil.

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA